Paromomycin sulfate: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
mNo edit summary
Line 1: Line 1:
{{Drugbox|
__NOTOC__
|IUPAC_name = (2''R'',3''S'',4''R'',5''R'',6''S'')-5-amino-6-[(1''R'',2''S'',3''S'',4''R'',6''S'')-<br>4,6-diamino-2-[(2''S'',3''R'',4''R'',5''R'')-4-[(2''R'',3''R'',4''R'',5''R'',6''S'')-<br>3-amino-6-(aminomethyl)-4,5-dihydroxy-oxan-2-yl]<br>oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-<br>3-hydroxy-cyclohexyl]oxy-2-(hydroxymethyl)oxane-3,4-diol
{{Paromomycin sulfate}}
| image=Paromomycin.svg
| CAS_number=1263-89-4
| ATC_prefix=A07
| ATC_suffix=AA06
| ATC_supplemental=
| PubChem=165580
| DrugBank=?
| C=23 | H=47 | N=5 | O=18 | S=1
| molecular_weight = 615.629 g/mol
| bioavailability= None
| metabolism = None
| elimination_half-life= ?
| excretion = Fecal
| pregnancy_US = C
| legal_status = Schedule VI <small>[[U.S.]]</small>
| routes_of_administration= Oral, [[Intramuscular injection|intramuscular]]
}}
{{SI}}
{{CMG}}
{{CMG}}


==Overview==
Paromomycin is an [[aminoglycoside]] antibiotic, first isolated from ''Streptomyces krestomuceticus'' in the 1950s.<ref name="Davidson2008">{{cite journal| author = Davidson R.N., den Boer M., Ritmeijer K. | year = 2008 | title = Paromomycin | journal = Transactions of the Royal Society of Tropical Medicine and Hygiene | volume = 103| issue = 7| pages = 653–60| doi = 10.1016/j.trstmh.2008.09.008| pmid = 18947845}}</ref> It was discovered by [[Parke Davis]] now [[Pfizer]] and introduced as ''Humatin'' in 1960.<ref>Page 1166. http://books.google.co.in/books?id=XCsJgUnclbcC&pg=PA1257&dq=Pharmaceutical+Manufacturing+Encyclopedia,+Volume+2&hl=en&sa=X&ei=9V7iT8mqJoOIrAfe4P2zAw&ved=0CDoQ6AEwAA#v=onepage&q=Pharmaceutical%20Manufacturing%20Encyclopedia%2C%20Volume%202&f=false</ref> It is also called monomycin and aminosidine.<ref name="Neal1994">{{cite journal |author= Neal R.A. ''et al''. |year=1994 |title=Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis |journal=Transactions of the Royal Society of Tropical Medicine and Hygiene |volume=88 |issue=2 |pages=223–5 | doi=10.1016/0035-9203(94)90307-7 |pmid= 8036682 }}</ref>


==Category==
Amebicide


'''Paromomycin sulfate''' (brand name '''Humatin''') is a drug that fights intestinal infections such as [[cryptosporidiosis]] and amoeba infection, or [[amoebiasis]] and was developed as a therapeutic against [[visceral leishmaniasis]] by the [[Institute for OneWorld Health]]. Paromomycin was granted [[orphan drug]] status in 2005<ref>{{cite press release
==US Brand Names==
|title=
PAROMOMYCIN SULFATE capsule<sup>®</sup>
Institute for OneWorld Health Drug Receives “Orphan” Designation From U.S. and European Regulatory Agencies
|publisher=Institute for OneWorld Health |date=23 May 2005
|url=http://www.oneworldhealth.org/media/details.php?prID=115 |accessdate=2007-02-10
}}</ref> and was approved by the Drug Controller General of India in September 2006 for treatment of visceral leishmaniasis.<ref>{{cite press release
|title=New cure for deadly visceral leishmaniasis (kala-azar) approved by government of India
|publisher=Institute for OneWorld Health |date=8 September 2006
|url=http://www.oneworldhealth.org/media/details.php?prID=154 |accessdate=2007-02-10
}}</ref>


Paromomycin inhibits [[protein synthesis]] by binding to 16S [[ribosomal RNA]].<ref>{{cite journal
==FDA Package Insert==
'''[[Paromomycin sulfate description|Description]]'''
'''| [[Paromomycin sulfate clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Paromomycin sulfate microbiology|Microbiology]]'''
'''| [[Paromomycin sulfate indications and usage|Indications and Usage]]'''
'''| [[Paromomycin sulfate contraindications|Contraindications]]'''
'''| [[Paromomycin sulfate warnings|Warnings]]'''
'''| [[Paromomycin sulfate precautions|Precautions]]'''
'''| [[Paromomycin sulfate adverse reactions|Adverse Reactions]]'''
'''| [[Paromomycin sulfate overdosage|Overdosage]]'''
'''| [[Paromomycin sulfate clinical studies|Clinical Studies]]'''
'''| [[Paromomycin sulfate dosage and administration|Dosage and Administration]]'''
'''| [[Paromomycin sulfate compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]'''
'''| [[Paromomycin sulfate directions for use|Directions For Use]]'''
'''| [[Paromomycin sulfate how supplied|How Supplied]]'''
'''| [[Paromomycin sulfate other size packages available|Other Size Packages Available]]'''
'''| [[Paromomycin sulfate labels and packages|Labels and Packages]]'''
 
==Mechanisms of Action==
Paromomycin is a [[protein synthesis inhibitor]] in non-resistant cells by binding to [[16S ribosomal RNA|16S]] [[ribosomal RNA]].<ref>{{cite journal
  | last = Vicens | first = Quentin | coauthors = Eric Westhof
  | last = Vicens | first = Quentin | coauthors = Eric Westhof
  | year = 2001 | month = August
  | year = 2001 | month = August
  | title = Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site | journal = Structure
  | title = Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site | journal = Structure
  | volume = 9 | issue = 8 | pages = 647&ndash;658
  | volume = 9 | issue = 8 | pages = 647–658
  | doi = 10.1016/S0969-2126(01)00629-3 | id = PMID 11587639
  | doi = 10.1016/S0969-2126(01)00629-3 | pmid = 11587639
  | url = http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VSR-43VBX2W-C&_user=10&_coverDate=08%2F31%2F2001&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=1b1e19d11ca34e14eca1603c2be009d5
  | url = http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VSR-43VBX2W-C&_user=10&_coverDate=08%2F31%2F2001&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=1b1e19d11ca34e14eca1603c2be009d5
  | accessdate = 2007-02-10
  | accessdate = 2007-02-10
  }}</ref>
  }}</ref> This broad spectrum antibiotic soluble in water, is very similar in action to [[Neomycin]]. Antimicrobial activity of Paromomycin against [[Escherichia coli]] and [[Staphylococcus aureus]] has been shown.<ref>{{ cite web | title = Paromomycin | url = http://www.toku-e.com/Upload/Products/PDS/20120518007094.pdf | format = pdf | publisher = Toku-E | date = 2010-01-12 | accessdate = 2012-06-11 }}</ref>


==References==
==References==
<References/>
{{Reflist|2}}
 
[[Category:Antiprotozoal agents]]
[[Category:Aminoglycoside antibiotics]]
[[Category:Orphan drugs]]
 
{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}}


[[de:Paromomycin]]
[[Category:Antibiotics]]
{{jb1}}
[[Category:Wikinfect]]
{{WH}}
{{WikiDoc Sources}}

Revision as of 20:25, 23 December 2013

Paromomycin Sulfate
PAROMOMYCIN SULFATE capsule®
FDA Package Insert
Description
Clinical Pharmacology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Paromomycin is an aminoglycoside antibiotic, first isolated from Streptomyces krestomuceticus in the 1950s.[1] It was discovered by Parke Davis now Pfizer and introduced as Humatin in 1960.[2] It is also called monomycin and aminosidine.[3]

Category

Amebicide

US Brand Names

PAROMOMYCIN SULFATE capsule®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Other Size Packages Available | Labels and Packages

Mechanisms of Action

Paromomycin is a protein synthesis inhibitor in non-resistant cells by binding to 16S ribosomal RNA.[4] This broad spectrum antibiotic soluble in water, is very similar in action to Neomycin. Antimicrobial activity of Paromomycin against Escherichia coli and Staphylococcus aureus has been shown.[5]

References

  1. ↑ Davidson R.N., den Boer M., Ritmeijer K. (2008). "Paromomycin". Transactions of the Royal Society of Tropical Medicine and Hygiene. 103 (7): 653–60. doi:10.1016/j.trstmh.2008.09.008. PMID 18947845.
  2. ↑ Page 1166. http://books.google.co.in/books?id=XCsJgUnclbcC&pg=PA1257&dq=Pharmaceutical+Manufacturing+Encyclopedia,+Volume+2&hl=en&sa=X&ei=9V7iT8mqJoOIrAfe4P2zAw&ved=0CDoQ6AEwAA#v=onepage&q=Pharmaceutical%20Manufacturing%20Encyclopedia%2C%20Volume%202&f=false
  3. ↑ Neal R.A.; et al. (1994). "Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis". Transactions of the Royal Society of Tropical Medicine and Hygiene. 88 (2): 223–5. doi:10.1016/0035-9203(94)90307-7. PMID 8036682.
  4. ↑ Vicens, Quentin (2001). "Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site". Structure. 9 (8): 647–658. doi:10.1016/S0969-2126(01)00629-3. PMID 11587639. Retrieved 2007-02-10. Unknown parameter |month= ignored (help); Unknown parameter |coauthors= ignored (help)
  5. ↑ "Paromomycin" (pdf). Toku-E. 2010-01-12. Retrieved 2012-06-11.
Retrieved from "https://www.wikidoc.org/index.php?title=Paromomycin_sulfate&oldid=919092"